Arcutis Biotherapeutics, Inc.
ARQT
Rank in Stocks
#4011
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Share Price
$32.04
Market Cap
$4.03B
Change (1 day)
0.47%
Change (1 year)
53.45%
Country
US
Trade Arcutis Biotherapeutics, Inc. (ARQT)
Category
Healthcare
Revenue for Arcutis Biotherapeutics, Inc. (ARQT)
Revenue in Jun 2026 TTM: $463.98M
According to Arcutis Biotherapeutics, Inc. latest financial reports the company's current revenue (TTM) is $463.98M. In 2023 the company made a revenue of $59.61M an increase over the revenue in the year 2022 that was $3.69M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Arcutis Biotherapeutics, Inc. from 2017 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $463.98M | 136.07% |
| 2024 | $196.54M | 229.74% |
| 2023 | $59.61M | 1,517.09% |
| 2022 | $3.69M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 2,620.87% |
US
|
|
| $2.23B | 380.19% |
US
|
|
| $15.74B | 3,293.31% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,197.74% |
NL
|
